HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hillhouse Capital Related

510.843

-19.317-3.64%

Number of Gainers:8

Number of Losers:43

Number of Flat:4

PE:- -

High:530.970

Open:530.107

Low:506.286

Close:530.160

Loading ...

Peijia Medical Completes First Two Implants with Transcatheter System; Shares Up 8%

MT Newswires Live

BUZZ-HK-listed Hbm at 3-year peak on getting paid for license deal

BRIEF-HBM Holdings Says Upfront Payment Received Under License Agreement With Windward Bio AG

Hbm Holdings - Upfront Payment Received Under License Agreement With Windward Bio Ag for Hbm9378/Skb378

THOMSON REUTERS

China Suntien Green Energy's (HKG:956) investors will be pleased with their splendid 170% return over the last five years

Simply Wall St.

After Leaping 26% Xinyi Energy Holdings Limited (HKG:3868) Shares Are Not Flying Under The Radar

Simply Wall St.

Chinese Regulator Accepts Second BLA for Anti-Inflammatory Drug Licensed by Hansoh Pharmaceutical

MT Newswires Live

Indonesian Regulator Approves NDA for Antengene's White Blood Cell Anti-Cancer Drug, Shares Up 11%

MT Newswires Live

BRIEF-Antengene Gets Approval Of NDA By Indonesia National Agency Of Drug And Food Control For Xpovio

Antengene Corp - Approval of Nda by Indonesia National Agency of Drug and Food Control for Xpovio

THOMSON REUTERS

BeiGene Says FDA Approves Tevimbra for Esophageal Cancer First-Line Treatment

MT Newswires Live

BRIEF-Hansoh Pharmaceutical Says Second Biologics License Application Of Xinyue Accepted By NMPA

Hansoh Pharmaceutical - Second Biologics License Application of Xinyue Accepted by Nmpa

THOMSON REUTERS

China Tower Corporation Limited's (HKG:788) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Simply Wall St.

Greater China Stocks Close Mixed; Hong Kong Leads Gainers

BeiGene's Q4'24 Loss Narrows

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/BK1583/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1583"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","market":"HK","secType":"PLATE","nameCN":"Hillhouse Capital Related","latestPrice":510.84283,"timestamp":1741594084374,"preClose":530.16,"halted":0,"volume":641110353,"delay":0,"changeRate":-0.036436,"change":-19.317139,"pbRate":2.561308,"amount":16897837474.6,"amplitude":0.04656,"prevYearClose":446.93042,"fiveDayClose":491.838,"twentyDayClose":478.478,"turnoverRate":0.004545,"marketCap":2846829146368,"floatMarketCap":2260124340224,"peRate":34.961436},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","high":530.9704,"amplitude":0.04656,"preClose":530.16,"low":506.28616,"pbRate":"2.561308","latestPrice":510.84283,"volume":641110353,"delay":0,"open":530.1071,"prevYearClose":446.93042,"prevWeekClose":530.16,"prevMonthClose":492.906,"prevQuarterClose":446.93,"fiveDayClose":491.838,"twentyDayClose":478.478,"sixtyDayClose":472.845,"secType":"PLATE","market":"HK","turnoverRate":0.004545,"peRate":34.961436,"marketCap":2846829146368,"floatMarketCap":2260124340224,"timestamp":1741594084374,"nameCN":"Hillhouse Capital Related"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1583\",,,,undefined,":{"bkCode":"BK1583","up":8,"down":43,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1583\",pageSize:16,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517002889","title":"Peijia Medical Completes First Two Implants with Transcatheter System; Shares Up 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517002889","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517002889?lang=en_us&edition=fundamental","pubTime":"2025-03-06 13:50","pubTimestamp":1741240218,"startTime":"0","endTime":"0","summary":"Peijia Medical  has completed the first two implants with the TrilogyTM Transcatheter Heart Valve System to treat severe aortic regurgitation in Taiwan, China, a Wednesday filing with the Hong Kong bourse said.The system is indicated for use in patients with symptomatic severe aortic regurgitation or symptomatic severe aortic stenosis who are at high risk for surgical aortic valve replacement.Shares of the company were up over 8% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09996","BK1583","BK1574","BK1100"],"gpt_icon":0},{"id":"2517901950","title":"BUZZ-HK-listed Hbm at 3-year peak on getting paid for license deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2517901950","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517901950?lang=en_us&edition=fundamental","pubTime":"2025-03-06 12:08","pubTimestamp":1741234095,"startTime":"0","endTime":"0","summary":"BUZZ-HK-listed Hbm at 3-year peak on getting paid for license deal** Shares of Chinese immunology diseases therapeutics developer Hbm Holdings Ltd 2142.HK rise 4.8% to HK$6.27, their highest since January 2022, and on course for second session of gains** Hbm says co, as a licensor in a license agreement for product HBM9378/SKB378, has received an upfront payment from licensee Windward Bio AG, which will bolster co's cash reserves** It gives no further details** Hong Kong's healthcare index .HSCIH climbs 1.1%, Hang Seng Index .HSI rises 2.5%** Stock up 221.5% YTD    ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nL2N3PP04E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","02142","BK1583"],"gpt_icon":0},{"id":"2517971674","title":"BRIEF-HBM Holdings Says Upfront Payment Received Under License Agreement With Windward Bio AG","url":"https://stock-news.laohu8.com/highlight/detail?id=2517971674","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517971674?lang=en_us&edition=fundamental","pubTime":"2025-03-06 08:52","pubTimestamp":1741222350,"startTime":"0","endTime":"0","summary":"BRIEF-HBM Holdings Says Upfront Payment Received Under License Agreement With Windward Bio AG March 6 (Reuters) - Hbm Holdings Ltd 2142.HK:UPFRONT PAYMENT RECEIVED UNDER LICENSE AGREEMENT WITH WINDWARD BIO AG FOR HBM9378/SKB378Further company coverage: 2142.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PO0J6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02142","BK1161","BK1583"],"gpt_icon":0},{"id":"2517975240","title":"Hbm Holdings - Upfront Payment Received Under License Agreement With Windward Bio Ag for Hbm9378/Skb378","url":"https://stock-news.laohu8.com/highlight/detail?id=2517975240","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517975240?lang=en_us&edition=fundamental","pubTime":"2025-03-06 08:00","pubTimestamp":1741219250,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PO0J6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02142","BK1583","BK1161","BK1574"],"gpt_icon":0},{"id":"2517105189","title":"China Suntien Green Energy's (HKG:956) investors will be pleased with their splendid 170% return over the last five years","url":"https://stock-news.laohu8.com/highlight/detail?id=2517105189","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517105189?lang=en_us&edition=fundamental","pubTime":"2025-03-06 07:20","pubTimestamp":1741216806,"startTime":"0","endTime":"0","summary":"The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551704-choice2-main-header/1585186816500","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551704-choice2-main-header/1585186816500"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/energy/hkg-956/china-suntien-green-energy-shares/news/china-suntien-green-energys-hkg956-investors-will-be-pleased","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1583","BK1558","BK1166","BK1503","BK1594","00956"],"gpt_icon":0},{"id":"2517131747","title":"After Leaping 26% Xinyi Energy Holdings Limited (HKG:3868) Shares Are Not Flying Under The Radar","url":"https://stock-news.laohu8.com/highlight/detail?id=2517131747","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517131747?lang=en_us&edition=fundamental","pubTime":"2025-03-06 07:14","pubTimestamp":1741216440,"startTime":"0","endTime":"0","summary":"Xinyi Energy Holdings Limited ( HKG:3868 ) shareholders would be excited to see that the share price has had a great...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9621063-choice2-main-header/1585186854995","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9621063-choice2-main-header/1585186854995"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/utilities/hkg-3868/xinyi-energy-holdings-shares/news/after-leaping-26-xinyi-energy-holdings-limited-hkg3868-share","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1154","BK1554","BK1583","BK1594","03868"],"gpt_icon":0},{"id":"2517648029","title":"Chinese Regulator Accepts Second BLA for Anti-Inflammatory Drug Licensed by Hansoh Pharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=2517648029","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517648029?lang=en_us&edition=fundamental","pubTime":"2025-03-05 15:54","pubTimestamp":1741161265,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group  said the second biologics license application or BLA of its antibody drug XINYUE  was accepted by the National Medical Products Administration or NMPA, a Tuesday bourse filing said.The drug is a targeted CD19 B cell-depleting antibody and is used to treat immunoglobulin G4-related disease, a chronic inflammatory condition.In May 2019, Viela Bio granted the group the exclusive license to develop and commercialize the drug in China, Hong Kong, and Macau.NMPA approved the launch of the drug in China in 2022, while the drug was also included in the national reimbursement drug list in 2023, a status that was renewed in November 2024.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK1589","03692","BK1191"],"gpt_icon":0},{"id":"2517697559","title":"Indonesian Regulator Approves NDA for Antengene's White Blood Cell Anti-Cancer Drug, Shares Up 11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517697559","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517697559?lang=en_us&edition=fundamental","pubTime":"2025-03-05 15:39","pubTimestamp":1741160361,"startTime":"0","endTime":"0","summary":"Antengene  obtained new drug application approval for three indications of XPOVIO  from the Indonesia National Agency of Drug and Food Control, a Wednesday Hong Kong bourse filing said.The indications include a combination with bortezomib and dexamethasone used for the treatment of multiple myeloma in adult patients, a combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma, and as a monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma in adult patients.Multiple myeloma is a cancer related to the white blood cells called plasma cells, while diffuse large B-cell lymphoma is cancer related to the white blood cells called lymphocytes.Shares of the company were up nearly 11% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","BK1191","BK1583","06996"],"gpt_icon":0},{"id":"2517969313","title":"BRIEF-Antengene Gets Approval Of NDA By Indonesia National Agency Of Drug And Food Control For Xpovio","url":"https://stock-news.laohu8.com/highlight/detail?id=2517969313","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517969313?lang=en_us&edition=fundamental","pubTime":"2025-03-05 15:28","pubTimestamp":1741159699,"startTime":"0","endTime":"0","summary":"BRIEF-Antengene Gets Approval Of NDA By Indonesia National Agency Of Drug And Food Control For XpovioMarch 5  - Antengene Corp Ltd 6996.HK:APPROVAL OF NDA BY INDONESIA NATIONAL AGENCY OF DRUG AND FOOD CONTROL FOR XPOVIOFurther company coverage: 6996.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PN0OV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06996","BK1583","BK1191"],"gpt_icon":0},{"id":"2517195939","title":"Antengene Corp - Approval of Nda by Indonesia National Agency of Drug and Food Control for Xpovio","url":"https://stock-news.laohu8.com/highlight/detail?id=2517195939","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517195939?lang=en_us&edition=fundamental","pubTime":"2025-03-05 12:00","pubTimestamp":1741147235,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PN0OV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06996","BK1583","BK1574","BK1191"],"gpt_icon":0},{"id":"2516689627","title":"BeiGene Says FDA Approves Tevimbra for Esophageal Cancer First-Line Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2516689627","media":"MT Newswires Live","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516689627?lang=en_us&edition=fundamental","pubTime":"2025-03-04 19:36","pubTimestamp":1741088212,"startTime":"0","endTime":"0","summary":"BeiGene  said Tuesday the US Food and Drug Administration approved Tevimbra, in combination with platinum-containing chemotherapy, for the first-line treatment of certain adults with unresectable or metastatic esophageal squamous cell carcinoma.The company said the approval is based on a phase 3 study where Tevimbra combination therapy showed a statistically significant improvement in overall survival.Tevimbra is also approved in the US as monotherapy for some patients with esophageal squamous cell carcinoma and in combination with chemotherapy for the first-line treatment of adults with gastric and gastroesophageal junction cancers, it added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1969619763.USD","BK4139","BK1500","BK1583","LU0307460666.USD","ONC","BK1588","LU2328871848.SGD","06160","BK1161","LU0588546209.SGD"],"gpt_icon":0},{"id":"2516629531","title":"BRIEF-Hansoh Pharmaceutical Says Second Biologics License Application Of Xinyue Accepted By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2516629531","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516629531?lang=en_us&edition=fundamental","pubTime":"2025-03-04 18:15","pubTimestamp":1741083310,"startTime":"0","endTime":"0","summary":"BRIEF-Hansoh Pharmaceutical Says Second Biologics License Application Of Xinyue Accepted By NMPAMarch 4  - Hansoh Pharmaceutical Group Company Ltd 3692.HK:SECOND BIOLOGICS LICENSE APPLICATION OF XINYUE ACCEPTED BY  NMPAFurther company coverage: 3692.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0GR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","03692","BK1191","BK1583"],"gpt_icon":0},{"id":"2516091626","title":"Hansoh Pharmaceutical - Second Biologics License Application of Xinyue Accepted by  Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2516091626","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516091626?lang=en_us&edition=fundamental","pubTime":"2025-03-04 18:12","pubTimestamp":1741083136,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0GR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","03692","BK1589","BK1583"],"gpt_icon":0},{"id":"2516619079","title":"China Tower Corporation Limited's (HKG:788) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?","url":"https://stock-news.laohu8.com/highlight/detail?id=2516619079","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516619079?lang=en_us&edition=fundamental","pubTime":"2025-03-04 07:52","pubTimestamp":1741045924,"startTime":"0","endTime":"0","summary":"China Tower (HKG:788) has had a great run on the share market with its stock up by a significant 11% over the last...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9022000-choice2-main-header/1585186701264","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9022000-choice2-main-header/1585186701264"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/telecom/hkg-788/china-tower-shares/news/china-tower-corporation-limiteds-hkg788-stock-on-an-uptrend","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00BHRH8C09.USD","BK1521","BK1506","BK1589","IE00BG0RBZ43.SGD","BK1529","IE00BHRH8D16.HKD","00788","BK1133","BK1583"],"gpt_icon":0},{"id":"2516502367","title":"Greater China Stocks Close Mixed; Hong Kong Leads Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2516502367","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516502367?lang=en_us&edition=fundamental","pubTime":"2025-03-03 16:30","pubTimestamp":1740990600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Stocks in Greater China were mixed on Monday.Hong Kong's Hang Seng Index rose 0.3% to 23006.27, and China's Shanghai Composite Index slipped 0.1% to 3316.93. The Taiwan Taiex index fell 1.3% to 22756.25.Among Hang Seng constituents, Li Auto Inc. posted the largest decline, falling 4.9%, followed by shares of Semiconductor Manufacturing International Corp., which fell 4.1%. Shares of BYD Electronic  Co. Ltd. fell 3.5%.Xinyi Solar Holdings Ltd. was the biggest gainer among companies on the Hang Seng, surging 8.5%, and JD Health International Inc. surged 5.0%. Alibaba Health Information Technology Ltd. rounded out the top three movers on Monday, as shares gained 3.4%.Among large mainland China stocks, UCloud Technology Co. Ltd. A posted the largest decline, dropping 13%, followed by shares of ASR Microelectronics Co. Ltd. A, which dropped 10%. Shares of Kangxin New Materials Co. Ltd. dropped 10%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00285","BK1571","LU0348766576.USD","IE00BZ08YR35.GBP","LU0051755006.USD","BK0214","LU0348767384.USD","688158","BK1582","688155","BK1515","BK1584","BK1504","IE00BZ08YS42.EUR","BK1189","BK1502","600076","BK1554","86618","BK1163","BK1526","00968","06618","BK1501","LU0456827905.SGD","688369","BK0217","BK0251","BK1607","IE00BZ08YT58.USD","BK1247","BK1610","BK1580","BK1583","BK0245","BK1169","688776","688220","LU1983299162.USD","BK1540","BK1149","BK0231","BK1142","LU0274383008.USD","BK1589","BK1591"],"gpt_icon":1},{"id":"2516048955","title":"BeiGene's Q4'24 Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2516048955","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516048955?lang=en_us&edition=fundamental","pubTime":"2025-03-03 16:20","pubTimestamp":1740990033,"startTime":"0","endTime":"0","summary":"BeiGene's  loss narrowed to $151.9 million in the fourth quarter of 2024 from $367.6 million in the year-ago period.Loss per share at the drug company narrowed to $0.11 from $0.27 in the previous year, according to a Thursday filing with the Hong Kong bourse.Total revenue surged to $1.12 billion from $630.5 million a year earlier.For 2025, full-year revenue is seen to range between $4.9 billion and $5.3 billion. It also forecasts positive GAAP operating income, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK1583","LU0307460666.USD","BK1588","LU1969619763.USD","688235","BK1161","06160","LU2328871848.SGD","LU0588546209.SGD","BK1500"],"gpt_icon":0}],"pageSize":16,"totalPage":6,"pageCount":3,"totalSize":84}]}}